Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on 11C-methionine PET: a retrospective, single-center study

Abstract The oncological and functional outcomes in glioblastoma (GBM) patients following supratotal resection (SupTR), involving complete of contrast-enhancing enhanced (CE) tumors areas methionine (Met) uptake on 11 C-met positron emission tomography (Met-PET), are unknown. We conducted a retrospective review newly diagnosed, IDH1 wild-type GBM patients, comparing SupTR with gross total (GTR), which only CE tumor tissue was resected. All underwent standard radiotherapy temozolomide treatment, were followed for recurrence overall survival (OS). Among the 30 included this study, 7 23 GTR. Awake craniotomy cortical subcortical mapping more frequently performed group than GTR group. During follow-up period, significantly different patterns disease progression observed between groups. Although 80% recurrences local group, all distant. Median OS groups 18.5 months (95% confidence interval [CI] 14.2–35.1) not reached CI 30.5-not estimable), respectively; difference statistically significant ( p = 0.03 by log-rank test). No postoperative neurocognitive decline evident who SupTR. Compared to alone, aggressive both Met (SupTR) under awake results benefit associated better control preservation.